EUCTR2016-001583-11-PL进行中（未招募）1 期
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin Chemotherapy - G1T28 safety and pharmacokinetic study in patients receiving etoposide and carboplatin
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age = 18 years
- •2. Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably including the presence of neuroendocrine features by immunohistochemistry
- •3. Extensive-stage disease
- •4. At least 1 target lesion that is unirradiated and measurable by RECIST, Version 1.1 (Eisenhauer 2009)
- •5. Hemoglobin = 9.0 g/dL
- •6. Absolute neutrophil count = 1.5 × 109/L
- •7. Platelet count = 100 × 109/L
- •8. Creatinine = 1.5 mg/dL OR glomerular filtration rate (GFR) of = 60 mL/min (by Cockcroft-Gault formula [Cockcroft and Gault 1976]); creatinine clearance calculated from an isotopic method or a 24-hour urine collection may be used instead of an estimated GFR by the Cockcroft-Gault formula
- •9. Total bilirubin = 1.5 × upper limit of normal (ULN)
- •10. AST and ALT = 2.5 × ULN; = 5 × ULN in the presence of liver metastases
- •11. Serum albumin = 3 g/dL
- •12. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •13. Predicted life expectancy of = 3 months
- •14. Contraception:
- •a. For females: All females of childbearing potential must have a negative serum beta human chorionic gonadotropin (ß-hCG) test result at screening and at baseline. Females must be either postmenopausal, surgically sterile, or using an acceptable method of contraception. Acceptable surgical sterilization techniques are hysterectomy, bilateral tubal ligation with surgery at least 6 months prior to dosing, and bilateral oophorectomy, with surgery at least 2 months prior to dosing. Acceptable methods of contraception are an intrauterine device, contraceptive implant, oral contraceptive (stable dose of the same hormonal contraceptive product for at least 3 months prior to dosing), a vasectomized partner, and a barrier method (condom or diaphragm) during the study and for 3 months after discontinuation of treatment
- •b. For males: Patients with female partner of childbearing potential must agree to use a highly effective form of birth control, which entails the use of oral, injected, or implanted hormonal methods of contraception or an intrauterine device/system by the female partner, in combination with a barrier method (eg, condom, diaphragm, cervical cap) during the study and for 3 months after discontinuation of treatment, and will also refrain from sperm donation for 3 months following completion of the study
- •15. Able to understand and sign an informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
排除标准
- •1. Prior chemotherapy for limited or extensive-stage SCLC
- •2. Presence of symptomatic brain metastases requiring immediate treatment with radiation therapy or steroids.
- •3. History of other malignancies, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated a) in situ carcinoma of the uterine cervix, b) prostate cancer, or c) superficial bladder cancer; or (3) other curatively treated solid tumor with no evidence of disease for = 3 years
- •4. Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure (Class III or IV as defined by the New York Heart Association [NYHA] functional classification system)
- •5. Known history of stroke or cerebrovascular accident within 6 months prior to enrollment
- •6. Serious active infection
- •7. Psychiatric illness/social situations that would limit study compliance
- •8. Other uncontrolled serious chronic disease or conditions that in the investigator’s opinion could affect compliance or follow-up in the protocol
- •9. Known human immunodeficiency virus (HIV), known hepatitis B virus (HBV), or known hepatitis C virus (HCV) positive that is symptomatic or requiring active therapy
- •10. Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response)
- •11. Receipt of any investigational medication within 4 weeks prior to enrollment
- •12. Hypersensitivity to any of the components of the formulation of etoposide or etoposide phosphate
- •13. Hypersensitivity to cisplatin or other platinum-containing compounds, or mannitol
- •14. Legal incapacity or limited legal capacity
- •15. Pregnant or lactating women
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to test the safety and plasma concentration of G1T28 in combination with topotecan in patients with previously treated extensive stage small cell lung cancerExtensive-Stage Small Cell Lung CancerEUCTR2016-004611-13-SKG1 Therapeutics90
进行中（未招募）
1 期
A clinical trial to test the safety and plasma concentration of G1T28 in combination with topotecan in patients with previously treated extensive stage small cell lung cancerExtensive-Stage Small Cell Lung CancerEUCTR2016-004611-13-BEG1 Therapeutics90
进行中（未招募）
1 期
A study to assess the safety and tolerability of combining G1T28 with etoposide and carboplatin therapy and to evaluate the effect of G1T28 on blood cell production affected by chemotherapy.EUCTR2016-001583-11-ESG1 Therapeutics110
进行中（未招募）
1 期
A clinical trial to test the safety and plasma concentration of G1T28 in combination with topotecan in patients with previously treated extensive stage small cell lung cancerMedDRA version: 20.0Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Extensive-Stage Small Cell Lung CancerEUCTR2016-004611-13-HRG1 Therapeutics90
进行中（未招募）
1 期
A clinical trial to test the safety and plasma concentration of G1T28 in combination with topotecan in patients with previously treated extensive stage small cell lung cancerMedDRA version: 19.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Extensive-Stage Small Cell Lung CancerEUCTR2016-004611-13-SIG1 Therapeutics60